<DOC>
	<DOCNO>NCT00247481</DOCNO>
	<brief_summary>This multicentre , randomise ( 2:1 ) , double blind , non-comparative phase II trial ZD1839 placebo combination chemotherapy patient metastatic breast cancer .</brief_summary>
	<brief_title>ZD1839 ( Iressaâ„¢ ) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer metastatic stage . Uni bidimensionally measurable lesion ( 10 mm 20 mm ) accord Response Evaluation Criteria Solid Tumours ( RECIST ) criteria World Health Organisation ( WHO ) performance status ( PS ) 0 2 Life expectancy great 12 week Normal cardiac function ( left ventricular ejection fraction [ LVEF ] isotopic examination great equal 55 % ) Symptomatic leptomeningeal metastasis Concomitant infectious disease Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy Incomplete heal previous oncologic surgery Absolute neutrophil count ( ANC ) less 1.5 x 109/litre ( L ) platelets less 100 x 109/L Serum creatinine great 1.5 time ULRR clearance &lt; 60 ml/min ALT AST great 2.5 time ULRR ALP &gt; 5 time ULRR ALP &gt; 2.5 time ULRR ALT AST great 1.5 time ULRR</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>